SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer
Phoenix, J. T.; Budreika, A.; Schmeck, D. A.; Kostlan, R. J.; Ferrari, M. G.; Young, K. S.; Rogers, C. S.; Deegan, C. D.; Bergom, H. E.; Boytim, E.; Brown, R. M.; Bienko, M. W.; Walewicz, J. A.; Bhagi, S. K.; Ellis, L.; Antonarakis, E. S.; Drake, J. M.; Bawa, P. S.; Vellky, J. E.; Williams, A.; Reizine, N. M.; Rennhack, J. P.; Fanning, S. W.; Hwang, J. H.; Szmulewitz, R. Z.; Vander Griend, D. J.; Kregel, S.
Show abstract
Treatment options and diagnostic outlook for men with advanced, therapy resistant prostate cancer (PCa) are extremely poor; this is primarily due to the common lack of durable response to androgen receptor (AR) targeted therapies and phenotypic transdifferentiation into a particularly lethal subtype known as neuroendocrine prostate cancer (NEPC). In this study, we mechanistically determine that SOX2 (a transcription factor originally repressed by AR) physically binds and acts in a concerted manner with FOXA1 (a key AR pioneering cofactor) to regulate a subset of genes which promote cell cycle progression, and lineage plasticity in AR-refractory prostate cancers. Our findings assert the SOX2/FOXA1 interaction as an important mediator of resistance to AR-targeted therapy and a driver of NEPC and lineage plasticity; their coordinated action and downstream signaling offers a potential novel therapeutic opportunity in late-stage PCa.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.